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Compound 2 (12.1 mg) was obtained as a pale yellow powder. HRESIMS data suggested a molecular formula of C19H16O3. The compound showed distinctive UV maxima at 202, 259, and 315 nm. The NMR data were in agreement with those reported for BTH-II0204-207:A, a terphenyl compound first reported in 2011 by Beggins et al. (16) from the pathogenic bacterium Burkholderia pseudomallei.
Compound 3 (6.2 mg) was obtained as an orange powder. The molecular formula was determined as C19H14O3 via HRESIMS, establishing an index of hydrogen deficiency of 13. The UV maxima (198, 235 , and 331 nm) and NMR data suggested structural similarity with compound 1, although a key difference was the loss of structural symmetry. Relative to 1, compound 3 also lacked one methoxy moiety, as supported by a 30 amu difference in the HRMS data. 1H NMR data (Table 1) revealed the presence of 10 aromatic protons (δH 7.45-7.52 for H-2′ to H-6′ and δH 7.33-7.42 for H-2″ to H-6″), suggesting two monosubstituted benzene rings, one olefinic proton (δH 6.88, H-6), and one methoxy group (δH 3.80, 3-OCH3). The 13C NMR data revealed the presence of 19 carbons, consistent with the molecular formula and indicative of two carbonyls, which were assigned as quinone carbons (δC 187.4 and 183.3, for C-1 and C-4, respectively), four olefinic carbons (δC 132.7, 155.4, 144.5, and 133.0, for C-2, C-3, C-5, and C-6, respectively), and 10 aromatic carbons (δC 130.7, 128.2, 129.0, 128.2, 130.7, 129.4, 128.8, 130.3, 128.8, and 129.4, for C-2′, C-3′, C-4′, C-5′, C-6′, C-2″, C-3″, C4″, C-5″, and C-6″, respectively). Thus far, the spectroscopic data accounted for 12 of the 13 degrees of unsaturation, and hence, the 13th degree completed the quinone ring. COSY data identified two spin systems, which corresponded to the aromatic protons of the two phenyl rings. An HMBC correlation was observed from 3-OCH3 to C-3, indicating the connectivity of the methoxy group. HMBC correlations from H-6 to C-4, C-2, and C-1′ were observed. NOESY correlations were observed from the olefinic proton H-6 to the equivalent C-2′/C-6′ and from the 3-OCH3 to the equivalent C-2″/C-6″ (Figure 1b) . The last structure elucidation hurdle was to verify whether the central ring was an ortho or para quinone, but the spectroscopic data were inconclusive, since the observed HMBC and NOESY correlations for the H-3 and the 3-OCH3 were equally valid for either substitution pattern. What increased the dilemma of the substitution pattern were contradictory NMR data that were published by two different research groups for a synthetic (17) and a natural (18) compound with the same molecular formula (compound 4). Our NMR data were in agreement with those reported by Singh and co-workers, except for one carbon where the 13C NMR data differed by about 12 ppm.(18) Sawayama et al. (17) reported the synthesis of 4, where clear differences were observed between the NMR data of synthetic and natural 4, and they stated that reexamination of the structure of natural 4 was "underway by Dr. S. B. Singh". However, since this reexamination has not been reported yet, compound 3 was crystallized from ethyl acetate at room temperature to give monoclinic crystals, and single-crystal X-ray diffraction established the structure of 3 with the carbonyl carbons para to each other (Figure 1a ). To be consistent with the literature, the trivial name betulinan C was ascribed to 3. (2) and BTH-II0204-207:C, for PDE inhibition activity against 11 PDE families. The latter was inactive, while 2 showed activity against PDE11 as well as four out of the five PDE4s that were examined. PDE4 is an essential regulator of the secondary messenger cAMP in numerous cell types, and the reduction in cAMP degradation by several inhibitors, such as rolipram, piclamilast, roflumilast, cilomilast, and tetomilast, has suggested a broad range of clinical applications for the treatment of asthma and chronic obstructive pulmonary disease (COPD), (20, 21) some types of brain tumors, (22, 23) and other inflammatory diseases. (24) In 2011, roflumilast (Daliresp) was approved by the U.S. FDA as the first selective PDE4 inhibitor to reduce COPD exacerbations.(25) Moreover, abnormal regulation of cAMP and/or cGMP metabolism upon altered expression and activity of PDE isoforms has been implicated in the pathogenesis of various types of cancer, including prostate cancer, colon cancer, hematological malignancies, melanoma, and brain tumors. (26, 27) On the basis of these reports, the effects of 1-3 on the activity of recombinant human PDE4B2(28) were evaluated; PDE4B is the predominant isoform present in human monocytes and neutrophils and is involved mainly in inflammation.(29) Of these, 3 was the most potent, with an IC50 value of 17 μM, followed by compounds 2 and 1, with IC50 values of 31 and 44 μM, respectively ( Figure 2 ; Table 2 ). Molecular docking and other computational approaches are being used increasingly to explore the ligand-binding interactions of PDE4 inhibitors.(30-33) As such, compounds 1-3 were docked into the crystal structure of human PDE4B using Glide Extra Precision. (34, 35) The docking protocol was verified by testing its ability to reproduce the experimental binding mode of cocrystallized rolipram (Supporting Information Figure S4 ). To this end, rolipram bound to the crystal structure was removed from the binding pocket and docked back into the cofactor binding site; the root-mean-square deviation between the predicted conformation and the observed X-ray crystallographic data was 1.1 Å, indicating the capability of the docking protocol to reproduce the binding mode of rolipram (Supporting Information Figure S4 ). Compounds 1-3 were docked into the cAMP binding site of PDE4B. The docking scores calculated with Glide correlated with the biological activity ( Table 2) ; compound 3 displayed the highest activity (IC50 value of 17 μM) and also the top-ranked docking score (−8.732 kcal/mol). In contrast, compound 1 had the lowest activity (IC50 value of 44 μM) and showed the lowest docking score (−8.071 kcal/mol). Finally, the pyrrolidinone rolipram was included, not only for the docking protocol validation, but also as a positive control in the enzymatic assay; rolipram was top ranked in both docking score and in vitro activity.
Compounds 1-3 and rolipram displayed a similar binding mode (Figures 3 and S5) . The two predicted hydrogen bonds between the free amino group of Gln443 and the cyclopentyloxy and methoxyphenyl groups of rolipram were in agreement with the observations derived from the crystallographic structure of PDE4B in complex with rolipram. As shown, Glide found a similar hydrogen bond with Gln443 and the carboxyl group for the most active compound, 3 ( Figure 3c and d); favorable π interactions with Phe446 in the binding pocket were also observed. Compounds 1 and 2 did not show hydrogen bonds with Gln433, but similar π interactions were predicted (Figures 3a, b and S5 ). Taken together, these observations suggested that the binging modes predicted with Glide for compounds 1-3 were reasonable.
Compounds 1-3 were assayed for cytotoxicity and antimicrobial activity. When tested against the three cancer cell lines MCF-7, H460, and SF268 (Supporting Information Table S1 ), compounds 2 and 3 showed moderate cytotoxicity, while 1 was inactive. Compounds 2 and 3 were equipotent against S. aureus, with MIC values of 25 μg/mL, while none of the compounds showed activity against C. albicans. In conclusion, three compounds (1-3) were isolated and characterized from the fungus MSX 47445. The structure of the new paraquinone, 3, was assigned unequivocally by NMR and single-crystal X-ray diffraction. The effect of compounds 1-3 on the activity of PDE4B was assessed both in vitro and in silico; compound 3 was the most potent, being approximately a half-order of magnitude less potent than the positive control, rolipram. Further studies are ongoing to expand the knowledge base of this class of compounds, particularly given their compact structures.
Experimental Section
General Experimental Procedures UV and IR spectra were acquired on a Varian Cary 100 Bio UV-vis spectrophotometer and a Perkin-Elmer Spectrum One with Universal ATR attachment, respectively. NMR experiments were conducted in either CDCl3, acetone-d6, or DMSO-d6 with TMS as a reference via a JEOL ECA-500, operating at 500 MHz for 1H and 125 MHz for 13C. HRESIMS was performed on a Thermo LTQ Orbitrap XL mass spectrometer equipped with an electrospray ionization source. UPLC was carried out on a Waters Acquity system with data collected and analyzed using Empower software. HPLC was carried out using a Varian Prostar HPLC system equipped with ProStar 210 pumps and a Prostar 335 photodiode array detector, with data collected and analyzed using Galaxie Chromatography Workstation software (version 1.9.3.2). For preparative HPLC, a Phenomenex Synergi Max-RP 80 (4 μm; 250 × 21.2 mm) column was used at a 21 mL/min flow rate, while for the semipreparative HPLC, a Phenomenex Gemini-NX C18 (4 μm; 250 × 10 mm) column was used at a 4.7 mL/min flow rate. For UPLC, a Waters BEH C18 column (1.7 μm; 50 × 2.1 mm) was used with a 0.6 mL/min flow rate. Flash chromatography was performed on a Teledyne ISCO CombiFlash Rf using a 40 g Silica Gold column and monitored by UV and evaporative light-scattering detectors. X-ray crystallography data were acquired using a Bruker APEX CCD diffractometer (Mo Kα̅ radiation, graphite monochromator). All other reagents and solvents were obtained from Fisher Scientific and were used without further purification.
Producing Organism and Fermentation
Mycosynthetix fungal strain 47445 was isolated from highly decomposed woody debris in 1990.
The growth conditions were as described previously (9, 12) and outlined in the Supporting Information. For molecular identification, the internal transcribed spacer regions 1 and 2 and 5.8S nrDNA (ITS) were sequenced, since this region of the rRNA operon has been proposed as a barcode marker for fungi.(36) Detailed methodology for DNA extraction, PCR amplification, sequencing, and phylogenetic analyses is outlined in the Supporting Information. The combined ITS and LSU sequence was deposited in GenBank (accession no. JX310275). The analyses of both the rRNA regions (ITS and D1/D2 of the LSU) suggested that MSX 47445 was a member of the Chaetothyriales, Ascomycota, and shares phylogenetic affinities with the mitosporic fungus Cyphellophora sp.
Extraction and Isolation
To the large-scale solid fermentation culture of MSX 47445 was added 500 mL of 1:1 MeOHCHCl3. The culture was chopped with a spatula and shaken overnight (∼16 h) at ∼100 rpm at rt. The sample was filtered with vacuum, and the remaining residues were washed with 100 mL of 1:1 MeOH-CHCl3. To the filtrate were added 900 mL of CHCl3 and 1500 mL of H2O; the mixture was stirred for 2 h and then transferred into a separatory funnel. The bottom layer was drawn off and evaporated to dryness. The dried organic extract was reconstituted in 300 mL of 1:1 MeOH-CH3CN and 200 mL of hexanes. The biphasic solution was stirred for an hour and then transferred to a separatory funnel. The MeOH-CH3CN layer was drawn off and evaporated to dryness under vacuum. The defatted material (1.2 g, orange-red) was dissolved in a mixture of CHCl3-MeOH, adsorbed onto Celite 545, and fractionated via flash chromatography using a gradient solvent system of hexane-CHCl3-MeOH at a 40 mL/min flow rate and 53.3 column volumes over 63.9 min to afford seven fractions. Fraction 2 eluted with 100% CHCl3 (∼247 mg) and was subjected to preparative HPLC using an isocratic system of 55:45 CH3CN-H2O over 30 min at a flow rate of 4.7 mL/min to yield seven subfractions. Subfraction 5 yielded compound 1 (30.2 mg), which eluted at ∼22.5 min. Subfraction 2 was subjected to semipreprative HPLC and yielded compounds 2 (12.1 mg) and 3 (6.2 mg), which eluted at 9.5 and 19.0 min, respectively. UPLC was used to evaluate the purity of 1-3 using a gradient solvent system that initiated with 20:80 CH3CN-H2O to 100% CH3CN over 4.5 min; all compounds were >97% pure (Supporting Information Figure S1 ). 
Cytotoxicity Assay
The cytotoxicity measurements against the MCF-7(37) human breast carcinoma (Barbara A. Karmanos Cancer Center), NCI-H460(38) human large cell lung carcinoma (HTB-177, American Type Culture Collection (ATCC)), and SF-268(39) human astrocytoma (NCI Developmental Therapeutics Program) cell lines were performed as described previously. (40, 41) Antimicrobial Assay
The compounds were screened for antimicrobial activity using an agar plate diffusion assay as described previously. (8) Phosphodiesterase Inhibitor Assay
The PDE inhibitor assay was performed at BPS Bioscience Inc. as described previously. For docking, the scoring grids were centered on the crystal structure of rolipram using the default bounding sizes. All structures were docked and scored using Glide. (35) The best docked poses were selected as the ones with the lowest Glide score; the more negative the Glide score, the
